OmniAb (NASDAQ:OABI – Get Free Report) is one of 39 public companies in the “Commercial physical research” industry, but how does it contrast to its competitors? We will compare OmniAb to similar businesses based on the strength of its profitability, institutional ownership, valuation, dividends, analyst recommendations, risk and earnings.
Volatility and Risk
OmniAb has a beta of -0.54, meaning that its stock price is 154% less volatile than the S&P 500. Comparatively, OmniAb’s competitors have a beta of 5.65, meaning that their average stock price is 465% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and recommmendations for OmniAb and its competitors, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OmniAb | 0 | 0 | 9 | 0 | 3.00 |
| OmniAb Competitors | 49 | 781 | 1319 | 30 | 2.61 |
Profitability
This table compares OmniAb and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OmniAb | N/A | -6.38% | -4.33% |
| OmniAb Competitors | -940.72% | -103.25% | -22.46% |
Valuation & Earnings
This table compares OmniAb and its competitors top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| OmniAb | $59.08 million | -$22.33 million | -24.56 |
| OmniAb Competitors | $1.69 billion | $77.14 million | 6.00 |
OmniAb’s competitors have higher revenue and earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
56.5% of OmniAb shares are owned by institutional investors. Comparatively, 52.9% of shares of all “Commercial physical research” companies are owned by institutional investors. 7.0% of OmniAb shares are owned by insiders. Comparatively, 13.7% of shares of all “Commercial physical research” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
OmniAb beats its competitors on 7 of the 13 factors compared.
OmniAb Company Profile
OmniAb, Inc., a biotechnology company, engages in the provision of therapeutic antibody discovery technologies in the United States. The company's discovery platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTau, which features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.
